Literature DB >> 24255570

Criminal or bystander: imatinib and second primary malignancy in GIST patients.

Tatsuo Kanda1.   

Abstract

Entities:  

Year:  2013        PMID： 24255570      PMCID： PMC3828432          DOI： 10.3978/j.issn.1000-9604.2013.10.15

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN： 1000-9604            Impact factor:   5.087


× No keyword cloud information.
  14 in total

1.  Co-existence of gastrointestinal stromal tumors with other primary neoplasms.

Authors:  Alper Sevinc; Mesut Seker; Ahmet Bilici; Nuriye Yildirim Ozdemir; Ramazan Yildiz; Basak Oven Ustaalioglu; Mehmet Emin Kalender; Faysal Dane; Halit Karaca; Cengiz Gemici; Mahmut Gumus; Suleyman Buyukberber
Journal:  Hepatogastroenterology       Date:  2011 May-Jun

Review 2.  Occurrence of other tumors in patients with GIST.

Authors:  Rinaldo Gonçalves; Eduardo Linhares; Rafael Albagli; Marcus Valadão; Bruno Vilhena; Sérgio Romano; Carlos Gil Ferreira
Journal:  Surg Oncol       Date:  2010-08-02       Impact factor: 3.279

Review 3.  Occurrence of other malignancies in patients with gastrointestinal stromal tumors.

Authors:  Abbas Agaimy; Peter H Wünsch; Leslie H Sobin; Jerzy Lasota; Markku Miettinen
Journal:  Semin Diagn Pathol       Date:  2006-05       Impact factor: 3.464

4.  Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.

Authors:  Abbas Agaimy; Peter H Wünsch; Ferdinand Hofstaedter; Hagen Blaszyk; Petra Rümmele; Andreas Gaumann; Wolfgang Dietmaier; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2007-01       Impact factor: 6.394

5.  High incidence of microscopic gastrointestinal stromal tumors in the stomach.

Authors:  Kaori Kawanowa; Yuji Sakuma; Shinji Sakurai; Tsunekazu Hishima; Yoshiaki Iwasaki; Kana Saito; Yoshinori Hosoya; Takashi Nakajima; Nobuaki Funata
Journal:  Hum Pathol       Date:  2006-09-25       Impact factor: 3.466

Review 6.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

Authors:  Heikki Joensuu; Aki Vehtari; Jaakko Riihimäki; Toshirou Nishida; Sonja E Steigen; Peter Brabec; Lukas Plank; Bengt Nilsson; Claudia Cirilli; Chiara Braconi; Andrea Bordoni; Magnus K Magnusson; Zdenek Linke; Jozef Sufliarsky; Massimo Federico; Jon G Jonasson; Angelo Paolo Dei Tos; Piotr Rutkowski
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

7.  Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms.

Authors:  Marek Wronski; Bogna Ziarkiewicz-Wroblewska; Barbara Gornicka; Wlodzimierz Cebulski; Maciej Slodkowski; Aleksander Wasiutynski; Ireneusz W Krasnodebski
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

8.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Coexistence of gastrointestinal stromal tumors with other neoplasms.

Authors:  Łukasz Liszka; Ewa Zielińska-Pajak; Jacek Pajak; Dariusz Gołka; Joanna Huszno
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

10.  Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.

Authors:  Tatsuo Kanda; Takashi Ishikawa; Seiichi Hirota; Kazuhito Yajima; Shin-ichi Kosugi; Manabu Ohashi; Satoshi Suzuki; Yasuoki Mashima; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  Jpn J Clin Oncol       Date:  2012-04-21       Impact factor: 3.019
View more
  6 in total

1.  Altered expression profile of micrornas in gastric stromal tumor.

Authors:  Jun Xiao; Qi-Xian Wang; You-Qing Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-12-16

2.  MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT.

Authors:  Rong Fan; Jie Zhong; Sichang Zheng; Zhengting Wang; Ying Xu; Shuyi Li; Jie Zhou; Fei Yuan
Journal:  Tumour Biol       Date:  2013-12-29

Review 3.  Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature.

Authors:  Jaclyn Frances Hechtman; Ronald DeMatteo; Khedoudja Nafa; Ping Chi; Maria E Arcila; Snjezana Dogan; Alifya Oultache; Wen Chen; Meera Hameed
Journal:  Ann Surg Oncol       Date:  2015-01-07       Impact factor: 5.344

Review 4.  The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  J Gastrointest Cancer       Date:  2015-12

5.  microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.

Authors:  Rong Fan; Jie Zhong; Sichang Zheng; Zhengting Wang; Ying Xu; Shuyi Li; Jie Zhou; Fei Yuan
Journal:  Clin Exp Med       Date:  2014-04-05       Impact factor: 3.984

6.  Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report.

Authors:  Meng-Jie Jiang; Shan-Shan Weng; Ying Cao; Xiao-Fen Li; Liu-Hong Wang; Jing-Hong Xu; Ying Yuan
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.